PathoGenetix is developing products and applications based on its proprietary Genome Sequence Scanning™ (GSS™) technology, which was initially developed to detect bio-threat pathogens in environmental samples.
The Genome Sequence Scanning technology has a long history of published research documenting the development of its basic principles, components and processes. PathoGenetix is exploring application of the GSS technology for rapid bacterial identification and strain typing in markets such as food safety testing, industrial microbiology, and clinical diagnostics and research.
The RESOLUTION™ Microbial Genotyping System, which incorporates GSS, isolates and analyzes genomic DNA directly from an enriched biological sample—without the need for a pure culture isolate—and provides results in just five hours.
Speeding Pathogen Traceback and Source Tracking for Food Safety
The company will launch the first commercial application of the RESOLUTION Microbial Genotyping System for food safety testing and public health investigations of foodborne illness outbreaks beginning in 2014.
The RESOLUTION System offers unmatched levels of speed, automation and accuracy for food safety testing and outbreak investigations. The only bacterial identification system that provides serotyping and strain typing from complex samples in under five hours, the RESOLUTION SYSTEM offers a dramatic reduction in time-to-answer for pathogen traceback and source tracking to help save time, money and lives.
From Direct Linear Analysis to Genome Sequence Scanning
Originally called Direct Linear Analysis (DLA), the core Genome Sequence Scanning (GSS) technology was developed under a five-year, $50 million Department of Homeland Security contract for detection of bio-threat pathogens in environmental samples. The company successfully completed the contract and built a series of advanced prototype biosensors designed for continuous, automated environmental monitoring.
The company was initially established as US Genomics and became PathoGenetix in conjunction with a financing in 2010 and the launch of a new commercial strategy. PathoGenetix closed a Series B financing in November 2011, raising an additional $11.5 million.